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Abstract 
Rationale: Cancer stem cells (CSCs) have been implicated as the seeds of therapeutic resistance and 
metastasis, due to their unique abilities of self-renew, wide differentiation potentials and resistance to most 
conventional therapies. It is a proactive strategy for cancer therapy to eradicate CSCs. Methods: Tumor 
tissue-derived breast CSCs (BCSC), including XM322 and XM607, were isolated by fluorescence-activated 
cell sorting (FACS); while cell line-derived BCSC, including MDA-MB-231.SC and MCF-7.SC, were purified by 
magnetic-activated cell sorting (MACS). Analyses of microRNA and mRNA expression array profiles were 
performed in multiple breast cell lines. The mentioned nanoparticles were constructed following the standard 
molecular cloning protocol. Tissue microarray analysis has been used to study 217 cases of clinical breast 
cancer specimens. Results: Here, we have successfully established four long-term maintenance BCSC that 
retain their tumor-initiating biological properties. Our analyses of microarray and qRT-PCR explored that 
miR-34a is the most pronounced microRNA for investigation of BCSC. We establish hTERT promoter-driven 
VISA delivery of miR-34a (TV-miR-34a) plasmid that can induce high throughput of miR-34a expression in 
BCSC. TV-miR-34a significantly inhibited the tumor-initiating properties of long-term-cultured BCSC in vitro 
and reduced the proliferation of BCSC in vivo by an efficient and safe way. TV-miR-34a synergizes with 
docetaxel, a standard therapy for invasive breast cancer, to act as a BCSC inhibitor. Further mechanistic 
investigation indicates that TV-miR-34a directly prevents C22ORF28 accumulation, which abrogates 
clonogenicity and tumor growth and correlates with low miR-34 and high C22ORF28 levels in breast cancer 
patients. Conclusion: Taken together, we generated four long-term maintenance BCSC derived from either 
clinical specimens or cell lines, which would be greatly beneficial to the research progress in breast cancer 
patients. We further developed the non-viral TV-miR-34a plasmid, which has a great potential to be applied as 
a clinical application for breast cancer therapy. 
Key words: cancer stem cells; breast cancer; targeted drug delivery; miR-34a; C22ORF28; therapeutic target. 
Introduction 
Cancer stem cells (CSCs), also known as 
tumor-initiating cells, have been implicated as the 
seeds of metastasis and sources of therapy resistance, 
due to their unique abilities of self-renew, wide 
differentiation potentials and resistance to most 
conventional therapies. It is an attractive therapy 
strategy for treating cancer to eradicate CSCs [1, 2]. 
However, long-term-cultured CSC lines are rarely 
 
Ivyspring  
International Publisher 
 Theranostics 2017, Vol. 7, Issue 19 
 
 
http://www.thno.org 
4806 
generated in most investigations, and the reported 
treatment effects and mechanisms within CSCs have 
been intensively questioned. It is difficult to make a 
distinction between therapeutic response and 
self-differentiation of CSCs. With a goal of unlocking 
this mystery, we isolated, identified and maintained 
tumor tissue-derived breast CSCs (BCSC) in our 
recent reported investigation [3]. In sum, prolonged 
maintenance of CSCs could be a great benefit for 
enabling research progress in patients with tumors. 
The tumor-initiating properties of CSCs 
distinguish them from the remainder of cancer cells, 
and play a key role in therapeutic resistance, evasion 
of cell death, as well as dormancy [4]. Therefore, it 
remains an effective approach to eradicate CSCs 
through regulating determinants of tumor-initiating 
properties. On the other hand, it is well known that 
microRNAs, a class of small non-coding RNAs, can 
post-transcriptionally mediate gene expression of 
neoplasm. Multiple researches indicated that 
microRNAs could efficiently induce pluripotent stem 
cells to generate cell lineage without stemness 
characteristics, mediate self-renewal of stem cells and 
even determine their cell fate [5-7]. Consequently, 
microRNA interference might potentially be 
implicated in the tumor-initiating properties and cell 
fate of long-term-cultured CSCs.  
Since conventional therapy is not effective 
against CSCs, novel therapeutic strategies applying 
nanoparticle systems to deliver target-specific 
molecules have become promising approaches for 
potentially eliminating them [8-10]. Nanomedicine, as 
one of the fastest growing applications of 
nanotechnology, presents several outstanding 
advantages over conventional chemotherapeutics: 
enhanced permeability and retention effect, better 
surface modification for active tumor targeting, 
tunability of drug release, as well as nano-carriers 
with various drug molecules and imaging agents [11]. 
Although both viral vectors and non-viral vectors are 
used for systemic delivery in clinical trials, non-viral 
vectors hold the superior advantages of large-scale 
production, high level of transduction efficiencies, 
low immunogenicity and well-tolerated toxicity in 
comparison with viral vectors [8]. Currently, growing 
evidences have shown that lipid nanoparticle 
technology would be a dominant non-viral 
technology to enable the enormous potential of gene 
therapy [12]. 
In our previous researches, we developed 
VP16-GAL4-WPRE integrated systemic amplifier 
(VISA) as a non-viral targeting vector [13]. This 
versatile non-viral VISA vector was successfully 
shown to selectively amplify the transcriptional 
activity of promoters, with virtually no toxicity in 
pancreatic tumors [13], lung cancer [14], ovarian 
cancer [15], hepatocellular carcinoma [16, 17], prostate 
cancer [18] and breast cancer [19-22]. Furthermore, we 
established the hTERT-promoter-based VISA vector 
that drives transgene expression in treating breast 
cancer [18, 20, 21]. Our group also found that 
VISA-enabled systemic delivery of BikDD reduces the 
population of short-term-isolated breast cancer 
initiating cells [19, 23]. Collectively, our 
above-mentioned investigations urge us to explore 
the therapeutic response of long-term-cultured BCSC 
to hTERT-promoter-based VISA vector. 
In the present study, we tried to exploit a feasible 
treatment for long-term-cultured BCSC based on our 
previous investigations. Preliminarily, we explored 
the most prominent microRNA for investigation in 
tumor tissue-derived or cell line-derived 
long-term-cultured BCSC. We further sought to 
determine the therapeutic effect of 
hTERT-promoter-based VISA delivery of the specific 
microRNA on prolonged maintained BCSC. In 
addition, we provided mechanistic insight into this 
therapeutic strategy and the tolerability of this 
non-viral liposomal nanoparticle. 
Methods 
Patients and animal study 
Informed consent was obtained from all patients. 
Studies involved in animal experiments and human 
breast cancer tumor collection were approved by the 
research ethics committee of Sun Yat-sen University 
Cancer Center (SYSUCC).  
Isolation and passage of long-term-cultured 
BCSC 
Tumor tissue-derived BCSC (XM322 and XM607) 
were isolated by fluorescence-activated cell sorting 
(FACS) as previously described [3]. Cell line-derived 
BCSC (MDA-MB-231.SC and MCF-7.SC) were 
purified by magnetic-activated cell sorting (MACS). 
The application of culture medium was as described 
previously [3]. Further details are available in 
Supplementary methods. 
Patients, tissues, tissue microarray 
construction (TMA) and 
immunohistochemistry (IHC) 
A total of 134 female patients who were 
hospitalized in SYSUCC from 2001 to 2006 were 
enrolled in our study. Four fresh tissue samples of 
breast tumors collected during eradicative operations 
performed at Sun Yat-Sen University Cancer Center in 
July 2015 were randomly chosen for the Western blot 
study. See Supplementary methods for details on data 
processing. 
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Constructs and transfection 
Detailed information of the VISA plasmid, 
hTERT promoter-driven VISA nanoparticle delivery 
of miR-34a (TV-miR-34a) and hTERT promoter-driven 
VISA nanoparticle delivery of control (TV-miR-Ctrl) 
were described previously [13, 22]. In brief, the 
miR-34a shRNA was incorporated into the Bgl II/Nhe 
I sites of the plasmid pGL3-T-VISA-Luc; following, 
the T-VISA-miR-34a fragment of pGL3-T-VISA-miR- 
34a was subcloned into the Not I and Sal I sites of 
pUK21. Transient transfections were performed as 
previously described [22]. Briefly, BCSC were 
transiently transfected with 1µg of the hTERT-VISA 
plasmid DNA using extruded DOTAP: cholesterol 
liposomes in 24-well plates (N/P ratio of 2:1). 
C22ORF28-Ad (addition of C22ORF28) and 
C22ORF28-KD (knockdown of C22ORF28) were 
generated as previously described [24, 25]. For 
site-specific mutagenesis, we mutated the regions in 
the C22ORF28-3'UTR and LIN28A-3'UTR 
complementary to the seed sequence of miR-34a using 
the QuikChange II Site-Directed Mutagenesis Kit. 
Further details are available in Supplementary methods. 
Flow cytometry 
Fluorescence-activated cell sorting (FACS) was 
performed to analyze the CD44+CD24- subpopulation, 
proportion of Lin and population of ALDH1 in BCSC 
using antibodies of CD44+, CD24-, Lin-PE and 
ALDH1-PE. Details are available in Supplementary 
methods. 
RNA isolation and real-time PCR 
The procedure for miR-34a expression was 
described previously [22]. Briefly, total RNA was 
extracted from BCSC using TRIzol Reagent 
(Invitrogen), according to the manufacturer’s 
instructions. The amount of mRNA was determined 
relative to 5S ribosomal RNA. Each sample was 
analyzed in triplicate. 
Serial passages of luciferase-labeled and green 
fluorescent protein (GFP)-labeled BCSC 
lineages 
Establishment protocols were described 
previously [3, 13]. Further details are available in 
Supplementary methods. 
Western blot analysis 
Protein extracts of BCSC (10 µg protein) were 
separated using 10% SDS-PAGE, and 
electrophoretically transferred to polyvinylidene 
difluoride (PVDF) membranes. Next, antibodies were 
assayed. We purchased primary antibodies of hTERT, 
C22ORF28, LIN28A and CD44 from Sigma-Aldrich 
Co. St Louis, USA. GAPDH was designed as a protein 
loading control.  
Telomerase activity assay 
Quantitative Telomerase Detection Kit (Allied 
Biotech, Vallejo, CA) was used to evaluate the 
telomerase activity in 1 µg of corresponding cell lysate 
according to the manufacturer’s instructions. 
MTT assay of cell viability 
MTT (Sigma) assay was used to assess cell 
viability according to the manufacturer’s instructions. 
Each assay was repeated five times. Further details 
are available in Supplementary methods. 
Clonal pair-cell analysis 
In brief, BCSC (5×106 cells) were transduced with 
GFP-labeled C22ORF28-KD plasmid for 48 h, stained 
with 2 µL DAPI (10 µg/mL) for 5 min, and 
counterstained with anti-CD44-PE (1:200) for 30 min, 
respectively. Preliminarily, GFP-labeled BCSC were 
purified and collected. Next, images were acquired by 
an inverted epifluorescence microscope system and 
further analyzed by digital confocal microscopy. 
Clonogenicity assay in soft agarose 
Clonogenicity assay in soft agarose was 
performed to determine clonal expansion ability of 
BCSC as previously described [3]. Further details are 
available in Supplementary methods. 
Tumor transplantation experiment 
To determine the optimum antitumor dose of 
T-VISA-miR-34a plasmid in vivo, a suspension of 
luciferase-labeled BCSC (1×104 cells) was inoculated 
at the left fourth inguinal mammary gland of female 
BALB/c-nude mice (6-week-old; Vital River 
Laboratories Animal, Beijing, China). Each group 
of mice received 100 µL of DNA-liposome complexes 
that contained 5 µg TV-miR-34a, 10 µg TV-miR-34a, 20 
µg TV-miR-34a, or liposomal complexes administered 
via tail vein injection, every other day / quaque omni 
die (qod) for 4 consecutive weeks. Moreover, to 
investigate the antitumor effect of TV-miR-34a in vivo, 
luciferase-labeled BCSC (1×104 cells) were injected 
into the left fourth inguinal mammary gland of mice. 
When the tumors reached ~50 mm3, the mice were 
noninvasively imaged using the IVIS system to 
confirm tumor growth and then randomly assigned to 
one of three following treatment groups (10 mice per 
group): Each group of mice received 100 µL of 
DNA-liposome complexes that contained 
TV-miR-Ctrl liposomal complexes (10 μg qod), 
TV-miR-34a liposomal complexes (10 μg qod) or 
liposomal (Ctrl) alone. The secretion levels of serum 
alanine transaminase (ALT), aspartate transaminase 
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(AST), blood urea nitrogen (BUN) and creatinine (Cr) 
were determined with an automatic analyzer (Roche 
Cobas Mira Plus; Roche, Mannheim, Germany). The 
secretion concentrations of cytokines (TNF-α, IL-6 and 
IFN-γ) in mouse sera were quantified using the 
cytometric bead array kit for mouse inflammatory 
cytokines (CBA; BD Biosciences). The test was 
repeated more than five times. See also in 
Supplementary methods.  
Microarray analysis 
RNA was tested by capillary electrophoresis on 
an Agilent 2100 bioanalyzer and high quality of 
samples was confirmed. Acquired images and the 
signal intensities of microRNA spots were evaluated 
by GeneSpring GX (Agilent Technologies, Capital 
Biochip Corporation) and normalized based on global 
signal intensity according to the manufacturer’s 
protocol. The results had been submitted to 
ArrayExpress (accession number E-MTAB-5584). The 
involved gene expressions of BCSC were described 
previously (accession number E-MTAB-5057) [3]. 
Further details are available in Supplementary methods. 
Statistical analysis 
All values are presented as the mean ± standard 
deviation (SD). For comparisons, Student’s t test 
(two-tailed), Wilcoxon signed-rank test, Pearson 
chi-square test, Pearson correlation analysis, Log-rank 
test, Fisher’s exact test, and nonparametric 
Mann-Whitney U test were performed as indicated. 
Survival rates were analyzed by log-rank test using 
SSPS 13.0 software. The significance level was set at p 
< 0.05. All data in our study have been recorded at 
Sun Yat-sen University Cancer Center for future 
reference (number RDDB2017000168). 
Results 
Identification of in vitro long-term-cultured 
BCSC  
In our previous work, we successfully generated 
and characterized two BCSC lines (BCSC1/XM322, 
Figure 1A left panel; and BCSC2/XM607, Figure 1A 
right panel) derived from 2 (out of 22) clinical 
specimens with surgically resected breast cancer. Both 
BCSC lineages showed prolonged maintenance over 
20 serial passages in vitro, while their tumor-initiating 
biological properties were retained [3]. To better 
investigate the innate features of BCSC, we further 
generated and maintained two BCSC lineages derived 
from breast cancer cell lines: MDA-MB-231.SC and 
MCF-7.SC. Here, we performed a magnetic-activated 
cell sorting (MACS) method to isolate cell line-derived 
BCSC, rather than using a fluorescence-activated cell 
sorting (FACS) approach for tumor tissue-derived 
BCSC. Both MDA-MB-231.SC and MCF-7.SC were 
isolated successfully and subsequently maintained on 
the first try. In a general sense, the success rate of cell 
line-derived BCSC isolated by MACS (2/2) is superior 
to that of tumor tissue-derived BCSC isolated by 
FACS (2/22) without removal of potential 
confounding factors (p < 0.05). Two cell line-derived 
BCSC sustained more than 20 passages for more than 
3 years. Both of the 20th serial passages of BCSC also 
held the properties of mammosphere, self-renewal 
(MDA-MB-231.SC, Figure 1B left panel; and 
MCF-7.SC, Figure 1B right panel), CD44+ CD24-/low 
(MDA-MB-231.SC, Supplementary figure S1A left 
panel; and MCF-7.SC, Supplementary figure S1A 
right panel), Lin- (Supplementary figure S1B) ALDH1+ 
(Supplementary figure S1C), and clonogenicity in soft 
agarose (Supplementary figure S1D). Consistent to the 
tumor tissue-derived BCSC we described in a 
previous study [3], as few as 1×103 BCSC were 
sufficient to enable formation into tumors 
(Supplementary figure S1E), while as many as 1×105 
breast cancer cells failed to generate tumors within 
two months according to the results of tumor 
transplantation experiment (Supplementary table S1). 
In sum, we successfully generated and maintained 
four long-term-cultured BCSC lineages. 
Microarray analyses of microRNA expression 
profiles to explore the most prominent 
microRNA expression in BCSC 
Since the hTERT-promoter-based VISA vector 
drives transgene expression in multiple tumors, we 
aimed to develop the hTERT-promoter-based VISA 
delivery of specific microRNA in order to treat 
malignant breast cancer cells (breast cancer cells and 
BCSC). First of all, we sought the lowest microRNA 
expressions in malignant breast cancer cells in 
comparison with healthy mammary epithelial cells 
(HME). By screening a genome-wide microRNA 
array, we explored significant differences of 
microRNA expressions among breast cancer cells (BC, 
including MDA-MB-231, MCF-7, MDA-MB-468 and 
SK-BR-3), BCSC (including MDA-MB-231.SC, 
MCF-7.SC, XM322 and XM607), and immortal HME 
(184A1 and MCF-12A) (Figure 1C and Supplementary 
table S2). We found that miR-34a is the most 
pronounced microRNA in microarray analyses. We 
further performed quantitative RT-PCR analysis to 
confirm these results. Compared with these two 
immortalized healthy mammary epithelial cell lines, 
miR-34a expression is significantly down-regulated in 
both groups of BCs and BCSC (Figure 1D). 
Additionally, miR-34a expression had no significant 
difference between groups of BCs and BCSC (Figure 
1D). To evaluate miR-34a expression in clinical 
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specimens, we retrospectively analyzed 
clinicopathological data of 134 patients from previous 
reports (Supplementary table S3) [3]. Quantitative 
RT-PCR analyses indicated that the expression level 
of miR-34a in the stage I-II group is lower than that in 
their adjacent healthy breast tissue specimens (HBT), 
and miR-34a expression within the stage III group 
was lowest among the three mentioned groups 
(Figure 1E). So, miR-34a is downregulated in human 
breast cancer cells and BCSC in comparison with 
healthy breast cells. Therefore, miR-34a is the most 
prominent microRNA for further investigation in 
long-term-cultured BCSC. 
 
 
Figure 1. miR-34a is the most pronounced microRNA for further research in long-term-cultured BCSC. (A) Capacities of self-renewal and sphere-formation of 
XM322 (left panel) and XM607 (right panel). Scale bar, 100 µm. (B) Capacities of self-renewal and sphere-formation of MDA-MB-231.SC (left panel) and MCF-7.SC (right panel). 
Scale bar, 100 µm. (C) Heatmap presents microRNA expressions among immortalized healthy mammary epithelial cells (HME, 184A1 and MCF-12A), breast cancer cells (BC, 
contained MDA-MB-231, MCF-7, MDA-MB-468 and SK-BR-3), and BCSC (contained MDA-MB-231.SC, MCF-7.SC, XM322 and XM607). (D) qRT-PCR analysis indicated that 
miR-34a expression of HME is significantly higher than that of BC and BCSC. miR-34a expression was normalized to the endogenous control 5S rRNA. NS: not significant. (E) 
qRT-PCR analyses indicated that samples within the stage I-II group had significantly lower miR-34a expression compared with those in groups of the adjacent healthy breast 
tissue specimens (HBT); additionally, miR-34a expression within stage III patients was lowest among the three groups. ***p<0.001.  
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Figure 2. Schematic illustration of TV-miR-34a (targeted expression of micro-RNA-34a by hTERT promoter-driven VISA) plasmid. (A) 
Schematic diagram; (B) Schematic structure.  
 
hTERT promoter-driven VISA delivery of 
miR-34a (TV-miR-34a) induces high 
throughput of miR-34a expression in BCSC 
In our previous reports, our group had 
established TV-miR-34a plasmid (Figure 2A) and 
found that TV-miR-34a can lead to high throughput of 
miR-34a in breast cancer cells. To elucidate the 
correlations among gene sequences, secondary 
structure and function, we precisely analyzed the 
gene sequences (Supplementary table S4) and 
schematic structure (Figure 2B) of TV-miR-34a 
(6973bp). Here we compared the expressions of 
human telomerase reverse transcriptase (hTERT) 
among the HME, BC and BCSC. Expressions of 
hTERT were rarely detectable in both HME cells; 
nevertheless, hTERT expressions were high in all BC 
and BCSC (Figure 3A). Similarly, telomerase activities 
in HME cells were significantly lower than that in 
either BCs or BCSC (Figure 3B). Telomerase activity 
within group of BCSC seemed to be higher than that 
of BCs; however, this association was only on the 
borderline (Figure 3B). Given the nature of metabolic 
inertness within BCSC, the transfection efficiency of 
TV-miR-34a nanoparticle in BCSC remains to be fully 
investigated. Therefore, determination of miR-34a 
expression within BCSC following TV-miR-34a 
transduction is very crucial for this therapeutic 
strategy. Since transfection efficiency depends on cell 
proliferation, transduction rates and other 
complicated factors [26], we aimed to select out 
transfected cells for further investigation. Initially, we 
established plasmids of GFP-labeled Ctrl, 
TV-miR-Ctrl and TV-miR-34a. Then, BCSC were 
transfected with the above-mentioned plasmids for 48 
h, respectively. Next, GFP-positive cells (both single 
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cell and pair cells) were purified by FACS (Figure 3C, 
representative images of XM322). Finally, telomerase 
activities among the HME, BC and BCSC had not been 
altered significantly after the corresponding 
transfection with Ctrl, TV-miR-Ctrl or TV-miR-34a, 
respectively (Figure 3D). In addition, miR-34a 
expressions in purified GFP-labeled BCSC were 
determined by quantitative RT-PCR. The normalized 
value of miR-34a/5s rRNA in TV-miR-34a-infected 
BCSC significantly increased from 206.56 ± 27.53 (n=3) 
to 255.59 ± 86.97 (n=3), while the miR-34a relative 
value in TV-miR-34a-infected BCs enhanced 
significantly from 322.87 ± 137.59 (n=3) to 405.77 ± 
162.17 (n=3) (Figure 3E). Here we found that there 
was no significant difference between BCs and BCSC 
following TV-miR-34a treatment (Figure 3E). In 
addition, cell viabilities were significantly depressed 
by TV-miR-34a treatment in both BCSC 
(MDA-MB-468, SK-BR-3, MDA-MB-231, MCF-7, 
parental cells of XM322 and XM607) and BCs 
(MDA-MB-231.SC, MCF-7.SC, XM322 and XM607) 
(Figure 3F). Meanwhile, this decrease was more 
pronounced in BCSC than in parental breast cancer 
cells, as depicted in Figure 3F. In sum, TV-miR-34a 
induces high throughput of miR-34a expression in 
BCSC, as well as preliminarily eradicates BCSC. 
TV-miR-34a significantly inhibits 
tumor-initiating properties of 
long-term-cultured BCSC in vitro 
In the beginning, we explored whether 
TV-miR-34a mediates the biological properties of 
BCSC. First, we transduced BCSC mammosphere 
with TV-miR-34a plasmid. We found that 
mammosphere of XM607 initiated to adherence and 
differentiation on day 3 (Figure 4A). Next, we found 
that TV-miR-34a reduced the proportion of 
CD44+CD24-, and this trend was more robust and 
persistent in comparison with Ctrl, miR-Ctrl, 
TV-miR-Ctrl or miR-34a in XM607; whereas the 
influence of miR-34a was transient and reversible 
(Figure 4B). Similar results were observed in 
MCF-7.SC (Supplementary figure S2). These findings 
were exciting because they implied that TV-miR-34a 
leads to the inhibition of tumor-initiating properties in 
BCSC. Consistent with the above results, we also 
found that TV-miR-34a decreased the clonogenicity 
ability of MCF-7.SC within soft agarose (Figure 4C).  
TV-miR-34a reduces proliferation of BCSC 
effectively and safely in vivo 
In our previous study, our group found that 
TV-miR-34a drastically eliminated breast cancer cells 
in vivo [22]. Here, we further investigated whether 
TV-miR-34a treatment plays a role in inhibiting BCSC 
proliferation. To confirm the therapeutic response of 
TV-miR-34a treatment in vivo, we initially established 
and maintained BCSC lineages expressing firefly 
luciferase. We found that TV-miR-34a inhibited the 
growth of BCSC-bearing tumors in mice by a 
dose-dependent manner. With the goal of achieving 
most efficacious antitumor activity with lowest 
potential toxicity, we selected an optimum dose (10 µg 
qod) for TV-miR-34a treatment in XM322-bearing 
mouse tumors (Figure 5A). Importantly, luciferase 
imaging revealed that treatment with TV-miR-34a led 
to significantly decreased bioluminescent signal from 
the tumors by day 10 after the first injection (Figure 
5B). Additionally, TV-miR-34a prolonged mouse 
survival even more effectively than either Ctrl or 
TV-miR-Ctrl (Figure 5C).  
Besides the efficacy of TV-miR-34a treatment, we 
also paid attention on its safety. Inconsistent to our 
previous work, [3] we found that body weights for all 
participating MDA-MB-231.SC-bearing nude mice did 
not change significantly (Figure 5D); suggesting that 
the dosage of 10 µg qod is better tolerated than 15 µg 
biw for TV-miR-34a, based on the treatment’s 
influence on body metabolism. In addition, liver 
injury in BALB/c-nude mice was assessed by 
measuring the levels of key liver enzymes in the 
serum. TV-miR-34a treatment did not affect serum 
alanine aminotransferase (ALT) (Figure 5E, left panel) 
and aspartate aminotransferase (AST) (Figure 5E, 
right panel) in MDA-MB-231.SC-bearing mice. 
Similarly, the effect of TV-miR-34a treatment on renal 
function of mice was further evaluated in 
MDA-MB-231.SC-bearing mice. We found no 
difference in levels of both blood urea nitrogen (BUN) 
(Figure 5F, left panel) or creatinine (Cr) (Figure 5F, 
right panel) among Ctrl, TV-miR-Ctrl and 
TV-miR-34a. All these parameters confirmed 
BCSC-bearing mice with TV-miR-34a treatment were 
physiologically healthy. 
The potential immunotoxicities of nanomaterials 
have received substantial attention. It is generally 
agreed that secretion amounts of proinflammatory 
cytokines can be useful tools in evaluating 
nanomaterial immunotoxicity [27]. In this study, we 
measured the serum proinflammatory cytokines 
(TNF-α, IL-6 and IFN-γ) to evaluate immunotoxicity 
produced by TV-imR-34a treatment in vivo. The 
differences in cytokine concentrations (TNF-α, IL-6 
and IFN-γ) between the groups of Ctrl-treated and 
TV-miR-Ctrl-treated mice were not statistically 
significant (Figure 5G). In comparison with groups of 
Ctrl and TV-miR-Ctrl, concentrations of TNF-α, IL-6 
and IFN-γ of mice in the study group of TV-miR-34a 
treatment were significantly increased from day 0 
to day 10 (Figure 5G). Remarkably, 10 days after 
 Theranostics 2017, Vol. 7, Issue 19 
 
 
http://www.thno.org 
4812 
injection of empty vector (liposome 100 µL) in mice, 
TNF-α was increased by 3.5-fold, relative to day 0 (p < 
0.001). The level of IL-6 was increased by ~3.0-fold 
relative to day 0 (p < 0.001). Similarly, the secretion 
amount of IFN-γ was increased by 5.7-fold as 
compared with day 0 (p < 0.001). Liposome injection 
increased immunomodulatory activities in mice in 
vivo, suggesting that there remains much space to 
develop the versatile empty vector. Although the 
mouse immune system was found to release 
significantly higher levels of proinflammatory 
cytokines (TNF-α, IL-6 and IFN-γ), we did not observe 
lethal inflammatory responses in mice throughout 
these tests. Therefore, treatment of TV-miR-34a for 
BCSC is well-tolerated in vivo. 
C22ORF28 (chromosome 22 open reading 
frame 28) acts as a direct and functional target 
of TV-miR-34a treatment in 
long-term-cultured BCSC 
Although multiple molecules have been 
reported to be direct targets of miR-34a in stem cells 
[5, 28], the precise molecular mechanisms of 
long-term-cultured BCSC repressed by TV-miR-34a 
remain to be established. In our recent research, we 
found that POMC, AKT2 and GSK3β could regulate 
the tumor-initiating properties of long-term-cultured 
BCSC [3]. Next, we speculated whether these 
molecules and their related signaling pathways are 
involved in the treatment mechanism of TV-miR-34a 
on BCSC. First, we used miRWalk 2.0 
(http://zmf.umm.uniheidelberg.de/apps/zmf/mirw
alk2) to predict RNA-binding proteins related to 
genes of AKT2, GSK3β and POMC (Supplementary 
table S5). C22ORF28-3'-UTR (Figure 6A) and 
LIN28A3'-UTR (Supplementary figure S3A) were 
determined to contain miR-34a-conserved binding 
sites. Second, we constructed a luciferase reporter 
vector comprising the 3'-UTR or 3'-UTR with 
mutation sites of C22ORF28 (Figure 6A) and LIN28A 
(Supplementary figure S3A). Encouragingly, 
TV-miR-34a significantly repressed luciferase 
expressions of Luc-C22ORF28-3'UTR rather than 
Luc-LIN28A-3'UTR; whereas the mutation of five 
nucleotides at the miR-34a-binding site of 
C22ORF28-3'UTR led to complete abrogation of the 
suppressive effect (Figure 6B and Supplementary 
figure S3B). In order to determine which molecule is 
acting as the functional target of TV-miR-34a in 
long-term-cultured BCSC, we performed Western 
blotting to measure expressions of C22ORF28, 
LIN28A and CD44. LIN28A expression was rarely 
detectable in all four BCSC. We further found that 
TV-miR-34a interference significantly inhibited 
expressions of C22ORF28 and CD44 rather than 
LIN28A (Figure 6C). Taken together, we conclude that 
C22ORF28 was the direct and functional target of 
TV-miR-34a in long-term-cultured BCSC.  
C22ORF28 mediates the inhibition effect of 
TV-miR-34a on tumor-initiating properties in 
long-term-cultured BCSC 
We further explored the role of C22ORF28 in the 
effect of TV-miR-34a on BCSC. Regulators of 
C22ORF28 were preliminarily established. We found 
that addition of exogenous C22ORF28 
(C22ORF28-Ad) up-regulated expressions of 
C22ORF28 and CD44; conversely, knockdown of 
C22ORF28 (C22ORF28-KD) down-regulated these 
expressions in BCSC (Figure 6D). Interestingly, 
C22ORF28-Ad increased the proportion of 
CD44+CD24- in BCSC; while C22ORF28-KD decreased 
their population (Figure 6E). Similarly, C22ORF28-KD 
inhibited the clonogenicity ability of XM322 within 
soft agarose; while C22ORF28-Ad promoted this 
ability (Figure 6F). Furthermore, clonal pair-cell assay 
was performed to evaluate the suppressive effect of 
C22ORF28-KD on XM607. Encouragingly, we 
indicated that C22ORF28-KD and CD44 were 
mutually exclusive of each other more often than they 
were co-expressed (Figure 6G). Collectively, these 
processes in vitro demonstrate that knockout of 
C22ORF28 could dramatically eliminate the 
tumor-initiating properties of long-term-cultured 
BCSC.  
With a goal of evaluating the effect of C22ORF28 
on the tumor-initiating biological properties of 
long-term-cultured BCSC, we generated GFP-labeled 
MDA-MB-231.SC (Supplementary figure S4). In 
comparison with the effect on day 0, day 1 and day 3, 
TV-miR-34a treatment significantly inhibited 
mammosphere formation of MDA-MB-231.SC on day 
5; while this effect was reversed by co-transfection of 
C22ORF28-3'-UTR rather than C22ORF28-3'-UTR-mut 
(Figure 7A and Figure 7B). These differences were 
further reflected by differences in GFP intensity. 
Compared with treatment of both Ctrl and 
TV-miR-Ctrl, TV-miR-34a significantly reduced the 
fluorescence intensity of BCSC to a similar extent in a 
time-dependent manner. Moreover, co-transfection of 
C22ORF28-3'-UTR could counteract the growth 
suppression mediated by TV-miR-34a in BCSC, 
whereas a mutation in the C22ORF28-3'-UTR binding 
sites of miR-34a did not have this effect (Figure 7A 
and Figure 7C). As presented in Figure 7D, 
C22ORF28-3'-UTR plasmid inhibited the eradication 
effect of TV-miR-34a on GFP-labeled BCSC; hence, 
C22ORF28-3'-UTR-mut plasmid conserved GFP 
expression during TV-miR-34a intervention. This 
result lent further credence to the notion that 
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TV-miR-34a targeted C22ORF28 directly and 
functionally in long-term-cultured BCSC. In a word, 
by targeting to C22ORF28 directly, TV-miR-34a 
attenuated the tumor-initiating properties of 
long-term-cultured BCSC. 
 
 
Figure 3. TV-miR-34a induces high throughput of miR-34a expression in BCSC. (A) Expression of hTERT was rarely detectable in both HME cells; while hTERT was highly 
expressed in all BC and BCSC. (B) Telomerase activities in HME cells were lower than BCs and BCSC. NS: not significant. (C) Representative images of isolated single cell (upper panel) and 
pair cells (low panel) expressing GFP-labeled TV-miR-34a in XM322. Scale bar, 5 µm (D) Telomerase activities among HME, BC and BCSC did not alter significantly following their 
corresponding transfection with Ctrl, TV-miR-Ctrl or TV-miR-34a, respectively. Scale bar, 5 µm.(E) qRT-PCR analysis demonstrated that TV-miR-34a plasmid significantly up-regulated 
miR-34a expression comparing with either TV-miR-Ctrl or Ctrl in both BCs and BCSC. (F) MTT assays of cell viabilities showed that TV-miR-34a decreased the cell viabilities in both BCSC 
(MDA-MB-468, SK-BR-3, MDA-MB-231, MCF-7, parental cells of XM322 and XM607) and BCs (MDA-MB-231.SC, MCF-7.SC, XM322 and XM607); whereas, cell viabilities of HME (MCF-12A 
and 184A1) were not found to be significantly different. The inhibitory effect of TV-miR-34a nanopartiple on cell viabilities of BCSC was stronger than their corresponding parental breast 
cancer cells. *p<0.05, **p<0.01, ***p<0.001  
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Figure 4. TV-miR-34a inhibits tumor-initiating properties of long-term-cultured BCSC in vitro. (A) Mammospheres of XM607 initiated adherence and 
differentiation following TV-miR-34a interference. Scale bar, 100 µm. (B) Representative images (left panel) and statistical results (right panel) of TV-miR-34a robustly 
and persistently decreasing the population of CD44+CD24- XM607; while miR-34a influence remained transient and reversible. (C) Representative images (left panel; 
scale bar, 100 µm) and statistical result (right panel) of clonogenesis abilities of MCF-7.SC down-regulated by TV-miR-34a. ***p<0.001. 
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Figure 5. TV-miR-34a suppresses proliferation effectively and safely in vivo. (A) TV-miR-34a inhibited the growth of luciferase-labeled XM322 bearing tumors in a 
dose-dependent manner. The optimum dose is 10 µg qod. (B) TV-miR-34a plasmid significantly suppressed fluorescence intensity of XM322 (upper left: representative images). 
(C) Kaplan-Meier survival analyses of TV-miR-34a prolonging mice survival in orthotopic xenograft models. (D) Body weights in all participant nude mice showed no significant 
change. (E) Side effects of TV-miR-34a treatment on serum ALT (left panel) and AST (right panel). (F) Side effects of TV-miR-34a treatment on serum BUN (left panel) and Cr 
(right panel). Each experiment was repeated more than three times. (G) In comparison with both groups of Ctrl and TV-miR-Ctrl, secretion levels of TNF-α (left panel), IL-6 
(middle panel) and IFN-γ (right panel) in the TV-miR-34a treatment group were significantly increased from day 0 to day 10. Each experiment was repeated more than three 
times. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 6. TV-miR-34a plays an inhibitory effect on tumor-initiating properties of long-term-cultured BCSC via directly targeting C22ORF28. (A) Schematic 
diagram of Luc-C22ORF28-3'UTR and mutation of Luc-C22ORF28-3'UTR (Luc-C22ORF28-3'UTR-mut) for presence of miR-34a conversed binding sites. (B) Mutating the 
predicted miR-34a binding sites within the Luc-C22ORF28-3'UTR luciferase reporter significantly abolished TV-miR-34a-dependent repression. (C) LIN28A is rarely detected in 
BCSC. Both C22ORF28 and CD44, rather than LIN28A, were the inhibitory targets of TV-miR-34a treatment. (D) Constructions of C22ORF28-Ad and C22ORF28-KD can 
effectively up-regulate and down-regulate expressions of C22ORF28 and CD44 in BCSC, respectively. (E) C22ORF28-Ad increased percentage of CD44+CD24- subpopulation 
cells in BCSC, whereas C22ORF28-KD decreased these subpopulation cells. (F) Representative images (left panel) and statistical results (right panel) of C22ORF28-Ad 
promoting sphere-formation ability within soft agarose of XM322, but C22ORF28-KD eliminating this ability. Scale bar, 100 µm. (G) Representative images (left panel) and 
statistical result (right panel) of TV-miR-34a suppressing CD44 expression measured by clonal pair-cell analyses in XM607. Scale bar, 10 µm; C.E.: co-expressed; M.E.: mutually 
exclusive. Each experiment was repeated at least three times. *p<0.05, **p<0.01, ***p<0.001.  
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Figure 7. Evaluation of the inhibitory effect of C22ORF28 intervene on long-term-cultured BCSC during TV-miR-34a treatment. (A) 
Representative images of mammosphere formation and fluorescence expression of GFP-labeled BCSC following transduction with Ctrl, TV-miR-Ctrl, TV-miR-34a, 
co-transfection of TV-miR-34a plus C22ORF28-3'-UTR, as well as co-transfection of TV-miR-34a plus C22ORF28-3'-UTR-mut, respectively (L.L.: lamp light; E.L.: 
exciting light). Scale bar, 100 µm. (B) Statistical results of differences in mammosphere formation. (C) Statistical results of fluorescence intensity. Each experiment was 
repeated at least in triplicate. (D) Schematic diagram of C22ORF28 mediating TV-miR-34a treatment in GFP-labeled long-term-cultured BCSC. **p<0.01, ***p<0.001.  
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TV-miR-34a synergizes with docetaxel for 
inhibition of BCSC  
In current clinical practice, the chemotherapeutic 
taxanes, represented by docetaxel and paclitaxel, are 
standard therapy for patients with invasive breast 
cancer. In this study, we examined whether the 
combination of TV-miR-34a and docetaxel may 
enhance the therapeutic effect on BCSC. Limitedly, 
docetaxel alone exerted no effect against 
MDA-MB-231.SC (Figure 8A and Figure 8B). 
However, we found that TV-miR-34a effectively 
sensitized GFP-labeled MDA-MB-231.SC to docetaxel. 
Docetaxel played a rare role in eradicating 
MDA-MB-231.SC: the inhibition effect of TV-miR-34a 
plus docetaxel on MDA-MB-231.SC was superior than 
that of TV-miR-34a alone (Figure 8A and Figure 8B). 
Similarly, docetaxel alone did not significantly affect 
cell viability of XM322; while XM322 with 
TV-miR-34a treatment showed a significant decrease 
in cell viability. In particular, combination treatment 
of TV-miR-34a plus docetaxel significantly decreased 
cell viability in XM322 more than single treatment 
alone using TV-miR-34a (Figure 8C). In line with these 
above-mentioned results, we found that TV-miR-34a 
alone significantly inhibited expressions of CD44 and 
C22ORF28 compared with either the vector or 
docetaxel treatment alone (Figure 8D). Further, the 
combined usage of TV-miR-34a plus docetaxel 
demonstrated even better inhibitory efficacy than 
single-agent application of TV-miR-34a plasmid 
(Figure 8D). Here we also found that LIN28A 
expression was rarely detectable in all four BCSC lines 
(Figure 8D). From the results of our previous 
investigations, TV-miR-34a plasmid significantly 
depressed the tumor-initiating properties of BCSC, 
thereby transforming their stem-like properties to 
non-stemness, along with inhibiting cell proliferation 
of BCSC (Figure 8E). These results suggested that the 
enhanced eradication effect induced by synergy of 
TV-miR-34a and docetaxel may contribute to their 
synergistic effects on the cell fate of BCSC, owing to 
the transformation of CD44 positive BCSC to 
non-stem-like tumor cells (Figure 8E).  
C22ORF28 is frequently up-regulated in breast 
tumor tissues, and positive expression is 
correlated with an unfavorable prognosis. 
Given the striking effect of C22ORF28 on 
TV-miR-34a treatment in long-term-cultured BCSC, 
we then questioned whether there was an association 
between C22ORF28 expression and clinical prognosis 
in patients with breast cancer. Here we evaluated 
C22ORF28 expression and other clinicopathological 
data from a previously reported study [3]. 
Representative slides of breast cancer tissues and 
corresponding adjacent healthy breast tissues are 
shown in Figure 9A and 9B. Expressions of C22ORF28 
were assessed by immunohistochemistry. We found 
that expression of C22ORF28 was conversely related 
to miR-34a level in breast cancer tissues 
(Supplementary table S6). These results were 
consistent with the response of miR-34a repressing 
C22ORF28 in BCSC. In addition, C22ORF28 positive 
probability in HBT was lower than that in patients 
with stage I-II, which was less than that in stage III 
(Supplementary table S6). To confirm these results of 
TMA and IHC, we further evaluated four cases of 
breast cancer tissues. Compared with HBT by 
Western blotting, the tumor tissues had a significantly 
higher expression of C22ORF28 (Figure 9C). Further 
Kaplan-Meier survival analyses showed that breast 
cancer patients with C22ORF28 positive expression 
had shorter disease-free survival (DFS) and overall 
survival (OS) than those patients with negative 
expression (Figure 9D). Moreover, we found a more 
favorable DFS and OS in the group that had high 
expression of miR-34a than in the group with low 
expression of miR-34a (Figure 9E). Therefore, 
up-regulation of C22ORF28 was common in patients 
with breast cancer, and C22ORF28 positive expression 
was associated with a more unfavorable patient 
prognosis. 
Discussion 
In this study, we have successfully generated 
four long-term-cultured BCSC that presented 
prolonged maintenance over 20 serial passages, while 
retaining their tumor-initiating properties. Analyses 
of microarray and qRT-PCR showed that miR-34a is 
the most pronounced microRNA for further BCSC 
investigation. We established hTERT promoter-driven 
VISA delivery of miR-34a plasmid, which can induce 
high throughput of miR-34a expression in BCSC. 
TV-miR-34a significantly inhibited tumor-initiating 
properties of the long-term-cultured BCSC in vitro, 
along with suppressing the proliferation of BCSC in 
vivo in an efficient and well-tolerated manner. Further 
mechanistic studies revealed that TV-miR-34a 
attenuates the tumor-initiating properties of 
long-term-cultured BCSC via targeting to C22ORF28 
directly. Furthermore, TV-miR-34a plasmid 
synergizes with docetaxel for eradicating BCSC. In 
addition, investigation of clinical implication showed 
that miR-34 and C22ORF28 have a negative 
correlation in breast tumor tissues. Also, positive 
expression of C22ORF28 is associated with an 
unfavorable prognosis. 
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Figure 8. TV-miR-34a has synergistic effects with docetaxel in eradication of BCSC. (A) MDA-MB-231.SC was observed with lamp light (L.L., left panel) 
or exciting light (E.L., right panel) to detect the depression effects. Scale bar, 100 µm. (B) Statistical results of differences in fluorescence expressions among groups 
of Ctrl, TV-miR-34a, and presence or absence of docetaxel 5 days following TV-miR-34a transduction. (C) MTT assay. (D) Docetaxel alone did not significantly alter 
expressions of CD44 and C22ORF28 in BCSC, compared to untreated cells. Combined application of TV-miR-34a plus docetaxel on BCSC for 48 h significantly 
decreased expressions of CD44 and C22ORF28 compared with TV-miR-34a alone. Cell line-derived (upper panel); tumor tissue-derived BCSC (low panel). (E) 
Schematic Diagram. All data corresponds to the mean ± SD of three independent experiments.. *p<0.05, **p<0.01, ***p<0.001.  
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Figure 9. C22ORF28 is frequently up-regulated in breast tumor tissues, and C22ORF28 positive expression is correlated with a poor prognosis. 
(A) Representative cases of breast cancer tissues immunostained with positive C22ORF28 (upper panel) and negative C22ORF28 (low panel). Scale bar, 100 µm. (B) 
Representative cases of adjacent healthy breast tissues immunostained with positive C22ORF28 (upper panel) and negative C22ORF28 (low panel). Scale bar, 100 µm. 
(C) Tumor tissues had a significantly higher expression of C22ORF28 than their adjacent healthy breast tissues (HBT). (D) Kaplan-Meier survival curves of 
disease-free survival (left panel) and overall survival (right panel) for C22ORF28 status in surgically resected breast cancer. (E) Kaplan-Meier survival curves of 
disease-free survival (left panel) and overall survival (right panel) for miR-34a status in surgically resected breast cancer. **p<0.01, ***p<0.001.  
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In term of BCSC generation, we found that the 
success rate for isolation of cell line-derived BCSC 
purified by MACS is higher than that for isolation of 
tumor tissue-derived BCSC purified by FACS. 
However, this result did not denote that MACS is 
always better than FACS in isolation of CSCs. 
Separating the cells based on their own cellular 
physical or biochemical properties, FACS and MACS 
have been developed into the most widely used 
techniques for cell sorting [29]. FACS method vibrates 
and analyzes each cell individually [30], therefore it 
may not be fit for maintenance of CSCs. However, the 
tumor tissue-derived CSCs were derived from the 
primary cells of human cancer tissues. In this case, 
FACS is efficient enough to exclude the extracellular 
matrix and the cells without stem-like properties. 
Alternatively, the MACS approach is beneficial due to 
its simplicity and robustness, not requiring 
sophisticated fluid handling [29]. So, we speculate 
that development of primary cell lines from tumor 
tissues will bring about a great advance in isolation of 
tumor tissue-derived CSCs. Multiple CSCs have been 
isolated and identified in recent decades [31]. 
However, long-term-cultured CSCs are rarely 
claimed. Here, we report four BCSC lineages that 
have been cultured for more than 20 serial passages 
and more than 3 years. We have to emphasize that 
application of proper culture medium, avoiding fungi 
infection and reducing unnecessary intense shock are 
crucial for long-term maintenance of BCSC, whether 
derived from tumor tissues or cell lines [3]. So, the 
feature of inertia within CSCs may reveal that they 
prefer a “quiet microenvironment” rather than 
dynamic conditions.  
The hypometabolism status of CSCs demands a 
highly specific and efficient amplification system to 
deliver anti-tumor molecules to eradicate them. VISA 
system is a non-viral system, which contains two basic 
elements: the two-step transcriptional amplification 
system (GAL4-VP2) and the WPRE sequence [13, 22]. 
WPRE plays a role in stabilizing 3'UTR of microRNA 
and enhancing the half-life of RNA transcripts. In 
addition, GAL4-VP2 combines and activates a 
therapeutic molecule. It is stated that the active 
human telomerase enzyme is mainly composed of 
hTERT, human telomerase RNA (hTR), and dyskerin. 
In this study, we found that both hTERT expression 
and telomerase activity in HME cells was significantly 
inferior to either BC or BCSC. We further found that 
hTERT promoter within TV-miR-34a can direct 
preferential transgene expression in cancer cells and 
BCSC rather than HME. Our results were consistent 
with the findings of Cao et al. for HME cells [32]. They 
interpreted that mRNA and protein expression of 
hTERT could be up-regulated in expressing 
exogenous hTERT amplified HME, but hTR limits 
telomerase activity and telomere maintenance in the 
context of hTERT amplification. This explanation 
indicated that TV-miR-34a drives the expression of 
miR-34a selectively in BCSC and CS, but does not 
drive its expression in HME.  
As illustrated in Figure 10, TV-miR-34a 
selectively controls the expression of miR-34a in BCSC 
in five steps: (1) The hTERT promoter drives 
expression of the GAL4-VP2 (two copies of VP16) 
fusion protein specifically in BCSC, rather than in 
adult stem cells; (2) the activator GAL4-VP2 is 
expressed; (3) GAL4-VP2 discerns the promoter 
G5E4T, due to G5E4T containing five GAL4 sites 
positioned upstream of the adenovirus E4 TATA box; 
(4) G5E4T induces the expression of the miR-34a 
shRNA transcripts, and then generates miR-34a; (5) 
the mature miR-34a are incorporated into the 
RNA-induced silencing complex (RISC), which 
induces downregulation of C22ORF28 leading to 
eradication of BCSC. In untransformed human 
tissues, most somatic cells lack telomerase activity, 
while somatic stem and progenitor cells express low 
levels of telomerase [33]. Of note, telomeres can form 
G-quadruplex structures (G4) in adult stem cells. 
Structures of G4 are highly stable and are difficult to 
resolve during replication, which can cause 
replication fork stalling (Figure 10) [33]. Additionally, 
chromosomal instability coming from replication 
stress can be ruled out by efficient checkpoints, which 
ensures the elimination of damaged stem cells and 
prevents stem cell-derived tumorigenesis [33]. It is 
well known that miR-34a has been identified as a 
tumor suppressor by several researches. It has been 
elucidated that p53 checkpoints and the p53-miR-34 
network can perform the second line of defense for 
avoiding abnormal proliferation in adult stem cells 
[33]. Therefore, the hTERT promoter has much less 
influence on adult stem cells, resulting in very limited 
target gene expression and therefore cell survival. 
Similarly, recent studies in human embryonic stem 
cells showed that increased TERT expression is not 
functionally associated with an increase in active 
telomerase, as hTR, but not TERT, is limiting [34]. 
Collectively, TV-miR-34a plasmid has the appropriate 
construction to eradicate BCSC via an efficient and 
safe approach. In the present study, in order to 
provide guidance for this novel therapeutic avenue, 
we have specifically analyzed the gene sequences and 
schematic structure of TV-miR-34a in detail. 
CSCs hold the tumor-initiating properties of 
self-renewal, proliferation, specific marker and 
differentiation [4, 35]. Interferences with adherence 
and differentiation are the critical directions for 
elimination of these progenitor cells. The therapeutic 
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approach with TV-miR-34a plasmid shows us the 
“dual steps” to eradicate BCSC. On the first step, 
findings regarding CD44+ CD24-/low differences, clonal 
pair-cell analyses and synergistic effects of docetaxel 
confirm that CD44+ CD24-/low BCSC are 
asymmetrically divided into CD44 negative 
heterogeneous lineages of breast cancer cells [3]. 
TV-miR-34a might restrict the acquisition of 
expanded cell fate potential in pluripotent stem cells 
through overexpression of miR-34a [5]. On the second 
step, as our previous study described, TV-miR-34a 
suppresses proliferation and invasion of breast cancer 
cells [22]. Therefore, miR-34a overexpressed by 
hTERT promoter-driven VISA plasmid can effectively 
eradicate BCSC.  
In the current research, we indicated that the 
non-viral TV-miR-34a nanoparticle showed great 
therapeutic efficacy in orthotopic xenograft models 
with a high degree of safety. TV-miR-34a treatment 
had no significant side effects on functions of liver 
and kidney in the participant mice. No lethal 
inflammatory responses were observed throughout 
the study. Here, we review plausible explanations for 
the increase of proinflammatory cytokines. First of all, 
this is essential for the nanomaterial to play a 
potential antitumor role in tumor-bearing mice [27]. 
Of note, the immune response is also influenced by 
the animal model. Kim and colleagues found that 
various proinflammatory cytokine levels are much 
higher in nude mice than wild-type mice after 
treatment [36]. So, the involved nude mice are more 
likely to produce a cytokine surge than wild-type 
mice. In sum, TV-miR-34a treatment for 
tumor-bearing mice is well-tolerated. 
There is increasing evidence that hypoxic 
microenvironment promotes renewal, differentiation, 
angiogenesis and accumulation of CSCs in tumor 
tissues. The hypoxia-inducible factors (HIFs) family, 
including HIF-1α, HIF-2α and HIF-3α, orchestrate 
signaling events regulating cell survival, proliferation 
and differentiation, angiogenesis, metabolism, 
invasion and metastasis of cancer cells, and is 
mediated prominently by HIF-1α and HIF-2α [37]. 
More recently, Li and colleagues found that miR-34a 
is directly repressed by HIF-1α under hypoxic 
conditions, and ectopic miR-34a prevents 
hypoxia-induced invasion and migration in hypoxic 
cancer cells [38]. Therefore, it is conceivable that 
miR-34a restored by TV-miR-34a may have 
therapeutic potential for hypoxia-driven formation of 
invasion and metastasis in tumor tissues. 
 
 
Figure 10. Schematic Diagram of the TV-miR-34a System. (A) The hTERT promoter drives expression of the GAL4-VP2 fusion protein selectively in BCSC, 
but not in adult stem cells (B) GAL4-VP2 is expressed; (C) GAL4-VP2 discerns the promoter G5E4T; (D) G5E4T promotes the expression of the miR-34a protein; 
(E) the mature miR-34a are incorporated into RISC, which inhibits C22ORF28 expression leading to eradication of BCSC. (F) Telomeres (mainly composed by 
hTERT) form G-quadruplex structures (G4), which along with G4 can cause replication fork stalling.  
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C22ORF28 is highly homologous to HSPC117 
(hematopoietic stem/progenitor cell 117) in humans, 
also previously known as focal adhesion associated 
protein (FAAP) in mice, and RTCB (RNA 2', 3'-cyclic 
phosphate and 5'-OH ligase) in prokaryotes. The high 
degree of conservation of C22ORF28/RTCB proteins 
from E. coli to human is suggestive of shared 
important roles for this protein family in organisms 
[39]. FAAP facilitates vinculin-paxillin association, 
decreases interaction of paxillin-focal adhesion kinase 
and reduces the phosphorylation of extracellular 
signal-regulated kinase in murine [40]. In the research 
of moving cells, Carmen et al. found that HSPC117 
might be involved in initiation of cell spreading by 
virtue of cell adhesion [41]. Recent investigations 
indicated that HSPC117 mediates tRNA [39, 42] and 
mRNA [25, 43] splicing. Herein, for the first time to 
our knowledge, we found that C22ORF28 maintains 
properties of self-renewal, proliferation, tumor 
formation, CD44+CD24- subpopulation and CD44 
expression in BCSC. In summary, we indicated that 
TV-miR-34a promotes adherence and differentiation 
in long-term maintenance of BCSC via targeting to 
C22ORF28. 
In conclusion, we generated long-term 
maintenance of BCSC, either from clinical samples or 
cell lines. We established the non-viral TV-miR-34a 
plasmid, which could eradicate long-term-cultured 
BCSC in a safe and efficient approach both in vitro and 
in vivo. The combination of TV-miR-34a and docetaxel 
enhanced the therapeutic effect on BCSC. Mechanistic 
studies further indicated that TV-miR-34a suppresses 
tumor-initiating properties, promotes adherence and 
boosts differentiation in long-term maintenance of 
BCSC through targeting C22ORF28 directly. Thus, we 
developed the non-viral TV-miR-34a plasmid, which 
has great potential for clinical application in breast 
cancer therapies targeting to BCSC.  
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